Xencor, Inc Leasehold Improvements, Gross
Xencor, Inc (XNCR) had Leasehold Improvements, Gross of $17.03 million as of 2021-09-30, per its 10-Q filed 2021-11-08.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent › Property, Plant, and Equipment, before Accumulated Depreciation, Depletion, and Amortization
us-gaap:LeaseholdImprovementsGross · last filed 2021-11-08
- 2021-09-30: Leasehold Improvements, Gross $17.03M.
- 2015-09-30: Leasehold Improvements, Gross $3.61M.
- 2015-06-30: Leasehold Improvements, Gross $3.20M.
- 2015-03-31: Leasehold Improvements, Gross $3.09M.
| Period end | Leasehold Improvements, Gross |
|---|---|
| 2021-09-30 | $17.03M 10-Q · filed 2021-11-08 |
| 2015-09-30 | $3.61M 10-Q · filed 2015-11-04 |
| 2015-06-30 | $3.20M 10-Q · filed 2015-08-05 |
| 2015-03-31 | $3.09M 10-Q · filed 2015-05-05 |
| 2014-12-31 | $3.09M 10-Q · filed 2015-11-04 |
| 2014-09-30 | $3.08M 10-Q · filed 2014-11-10 |
| 2014-06-30 | $3.08M 10-Q · filed 2014-08-01 |
| 2014-03-31 | $3.08M 10-Q · filed 2014-05-15 |
| 2013-12-31 | $3.08M 10-K · filed 2015-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |